iifl-logo-icon 1

Norris Medicines Ltd Share Price

13.86
(0.00%)
Jul 18, 2024|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open13.59
  • Day's High13.86
  • 52 Wk High27.51
  • Prev. Close13.86
  • Day's Low13.59
  • 52 Wk Low10.56
  • Turnover (lac)0.07
  • P/E0
  • Face Value10
  • Book Value-13.55
  • EPS0
  • Mkt. Cap (Cr.)13.86
  • Div. Yield0
No Records Found

Norris Medicines Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

13.59

Prev. Close

13.86

Turnover(Lac.)

0.07

Day's High

13.86

Day's Low

13.59

52 Week's High

27.51

52 Week's Low

10.56

Book Value

-13.55

Face Value

10

Mkt Cap (₹ Cr.)

13.86

P/E

0

EPS

0

Divi. Yield

0

Norris Medicines Ltd Corporate Action

29 Dec 2023

12:00 AM

EGM

arrow

18 Nov 2023

12:00 AM

AGM

Announcement Date: 18 Nov, 2023

arrow

22 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

21 Nov 2023

12:00 AM

BookCloser

arrow

Norris Medicines Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Norris Medicines Ltd SHAREHOLDING SNAPSHOT

21 Jul, 2024|12:18 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 34.01%

Foreign: 0.00%

Indian: 34.01%

Non-Promoter- 0.07%

Institutions: 0.06%

Non-Institutions: 65.91%

Custodian: 0.00%

Share Price

Norris Medicines Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

9.93

9.93

9.93

9.93

Preference Capital

0

0

0

0

Reserves

-22.37

-20.62

-17.36

-12.39

Net Worth

-12.44

-10.69

-7.43

-2.46

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

12.25

7.84

13.57

20.45

yoy growth (%)

56.19

-42.2

-33.65

8.48

Raw materials

-8.74

-4.52

-6.84

-10.4

As % of sales

71.34

57.67

50.4

50.84

Employee costs

-3.1

-3.22

-4.93

-5.3

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

-3.99

-3.68

-3.18

-1.18

Depreciation

-0.66

-0.72

-0.7

-0.64

Tax paid

-0.96

0.83

0.67

0.41

Working capital

-5.79

5.62

-2.44

-2.57

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

56.19

-42.2

-33.65

8.48

Op profit growth

-19.05

12.27

2,443.81

-109.04

EBIT growth

-15.71

12.46

327.74

-209.11

Net profit growth

74.64

13.08

227.43

-2,127.21

View Ratios

No Record found

Norris Medicines Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,593.65

125.293,82,370.02867.60.855,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,582.3

77.221,21,645.675310.652,259507.93

Cipla Ltd

CIPLA

1,506.05

32.741,21,616.251,038.40.563,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,185.3

34.71,19,268.911,405.20.253,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,665.1

25.951,11,193.661,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Norris Medicines Ltd

Management

Register Office

Registrar Office

Managing Director

Vimal D Shah

Independent Director

Hiten Parikh

Independent Director

S A M Azmathullah

Independent Director

Susmita Mahapatra

Company Sec. & Compli. Officer

Prerna Karwa

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Norris Medicines Ltd was established in September, 1990 as a small scale unit at GIDC Estate, Ankleshwar to manufacture non sterile dosage e.g. tablets, capsules, Liquid Orals, Copical ointments. The Company was subsequently converted into Public Limited Company on 7th March 1992. The unit expanded to manufacture Sterile dosage in form of Ampoules & Vials. The Company got into the business in the year 1990. Commercial production of the formulation unit commenced in Nov.91. The project commence in March 1992. Thereafter, the Company came out with a Public Issue aggregating Rs 5 cr in Dec.93 to expand its existing capacity for tablets, capsules, etc, besides diversifying into bulk drugs and setting up an injectables unit. The project costing Rs 14.21 Crore was financed through loans and equity, which got completed in 1995.In 2006, the Company launched Diabetic & Cardiac products; launched Dental product in 2007; launched New Molecule Tolperisone with Paracetamol tablet in 2012; in 2013, it extended Anti malarial range with Artemether Lumefantrine tablet & dry syrup. During the year 2013-14, the Company undertook the upgradation of Sterile Injectable Plant. The Company is one of the leading Indian manufacturers of Injections and Medicinal formulations. The Company is engaged into Health Care Industry and has 2 plants situated at GIDC, Ankleshwar, Gujarat. Both plants of the Company are WHO cGMP approved. At present, it has renovated the Sterile Injectable Plant, which is as per
Read More

Company FAQs

What is the Norris Medicines Ltd share price today?

Down Arrow

The Norris Medicines Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹13.86 today.

What is the Market Cap of Norris Medicines Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Norris Medicines Ltd is ₹13.86 Cr. as of 18 Jul ‘24

What is the PE and PB ratio of Norris Medicines Ltd?

Down Arrow

The PE and PB ratios of Norris Medicines Ltd is 0 and -1.02 as of 18 Jul ‘24

What is the 52 Week High and Low of Norris Medicines Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Norris Medicines Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Norris Medicines Ltd is ₹10.56 and ₹27.51 as of 18 Jul ‘24

What is the CAGR of Norris Medicines Ltd?

Down Arrow

Norris Medicines Ltd's CAGR for 5 Years at 8.42%, 3 Years at 20.36%, 1 Year at 7.86%, 6 Month at -25.28%, 3 Month at -0.86% and 1 Month at 19.79%.

What is the shareholding pattern of Norris Medicines Ltd?

Down Arrow

The shareholding pattern of Norris Medicines Ltd is as follows:
Promoters - 34.01 %
Institutions - 0.07 %
Public - 65.92 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.